Copyright 2014 Brand Exponents All Rights Reserved
Creating next generation products & solutions that will change lives
Academy Research Fellow, Associate Professor, Group Leader
Tomi´s group investigates the therapeutic potential and underlying neurobiological mechanisms of sedatives and anesthetics, particularly volatile and gaseous, against nervous system disorders associated with compromised neuronal plasticity.
PhD Student, Pharmacist
Neuropharmacology of rapid acting antidepressant drugs, neurotrophic signaling pathways, protein phosphorylation
Marko's studies include research on developmental neuroplasticity, different anesthetics’ and sedatives’ effects on neurotrophic signaling in the brain, their behavioral effects, and antidepressant potential.
Effects of rapid-acting antidepressants on metabolic and circadian regulation, signaling pathways of rapid-acting antidepressants, psychedelic therapy.
Commercialization, business consultant
Dr. Tomi Rantamäki has master´s degree in pharmacy (2003, University of Eastern Finland), a PhD degree in pharmacology and neuroscience (2006, University of Helsinki, Finland) and a docentship (Adjunct Professor) in neuropharmacology (2011, University of Helsinki). In 2014 he received the Fellowship grant from the Academy of Finland and with this grant he was able to establish his research group to the University of Helsinki. Tomi´s group investigates the therapeutic potential and underlying neurobiological mechanisms of sedatives and anesthetics, particularly volatile and gaseous, against nervous system disorders associated with compromised neuronal plasticity. Main focus is in discovering novel rapid-acting treatment concepts for depression. Tomi has >30 peer-review publications (H-index 17; >1200 citations) in scientific journals including Neuropsychopharmacology, Journal of Neuroscience, Neurobiology of Disease and Developmental Neurobiology. He is a Member of Council in the Brain Research Society Finland (BRSF) and a member in the following societies: BRSF, Federation of European Neuroscience Communities (FENS), Society for Neuroscience (SfN), Finnish Pharmaceutical Association and Finnish Pharmacological Society. He has been a reviewer in >20 journals including Neuropharmacology, Scientific Reports and International Journal of Neuropharmacology. Tomi has been 2 times a PhD thesis opponent, 3 times a docentship reviewer, 7 times a PhD thesis reviewer and has supervised 4 PhD students.
Jaana Heinonen (MBA) has master’s degree in international business management. She has worked over nine years in banking industry, e.g. as project manager, business consultant, business developer, and business banker. In 2016 she did her Master’s Thesis at Tampere University of Technology investigating the commercialization possibilities of a new cleantech related invention. She is keen to develop new solutions especially for healthcare sector.
Samuel Kohtala has a master’s degree in pharmacy (2015, University of Helsinki), and he is currently preparing his PhD thesis regarding the neuropharmacological effects of rapid acting antidepressant drugs. He is especially looking at pathways related to neurotrophic signaling and investigating putative novel rapid-acting treatments of depression, especially ketamine, nitrous oxide and psilocybin. Samuel also actively participates in scientific outreach activities, where he takes advantage of his previous artistic endeavors in news writing, editing, graphic design and audiovisual production.
Marko Rosenholm has a master’s degree in pharmacy (2016, University of Helsinki) and is currently working on his PhD degree with a particular focus on shared neurobiological mechanisms of various rapid acting antidepressant drugs. His studies also include research on developmental neuroplasticity, different anesthetics’ and sedatives’ effects on neurotrophic signaling in the brain, their behavioral effects, and antidepressant potential.
Okko has a master’s degree in pharmacy (2017, University of Eastern Finland) and a vocational degree in pharmaceutical marketing communications (2016, Institute of Marketing). Okko has previously worked at University of Eastern Finland, Charles River Laboratories, and A.I. Virtanen Institute. His research is focused on the effects of rapid-acting antidepressants on metabolic and circadian regulation. In addition, Okko is studying the signaling pathways mediating the effects of antidepressant drugs and pharmacotherapy using psychedelics. Okko has extensive background in arts and IT, so his work at laboratory also involves graphic design and website administration.